Chemotherapeutic and cytotoxic drugs are widely used in the treatment of cancer. In spite of
the improvements in the life quality of patients, their effectiveness is compromised by several …

Despite the gradual decrease in incidence, gastric cancer is still the third leading cause of
cancer death worldwide. Although chemotherapy enhances overall survival and quality of …

Background Evidence is scarce for the effectiveness of therapies for oesophageal cancer
progressing after chemotherapy, and no randomised trials have been reported. We aimed to …

Purpose Amplification of the MET proto-oncogene in gastroesophageal cancer (GEC) may
constitute a molecular marker for targeted therapy. We examined a GEC cohort with follow …

Purpose: Esophageal cancer is an aggressive malignancy and often resistant to therapy.
Overexpression of EGFR has been associated with poor prognosis of patients with …

Esophageal and Esophagogastric Junction Cancers in: Journal of the National
Comprehensive Cancer Network Volume 9 Issue 8 (2011) Jump to Content User Account …

Aims: Epidermal growth factor receptor (EGFR) expression has been observed in a variety of
solid tumours with the potential of new targeted therapeutic agents. The aim was to evaluate …

Metastatic gastric cancer is a lethal disease characterized by a very short overall survival,
underlining a critical need of new therapeutic options. Unfortunately, although several …

The characterization of oesophageal and gastric cancer into subtypes based on genotype
has evolved in the past decade. Insights into the molecular landscapes of gastroesophageal …

Purpose: HER2 amplification occurs in 18% to 27% of gastric and gastroesophageal
junction cancers. Lapatinib, a potent ATP-competitive inhibitor simultaneously inhibits both …